These studies confirmed tamoxifen’s role in significantly reducing the incidence of ER+ breast cancers, thus solidifying its place as the first-line agent in pharmacoprevention for premenopausal and select postmenopausal women at high risk. This evidence concerns the gene ESR1 and breast cancer.